Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

Possible Role of Coenzyme Q10 in Prevention of Contrast Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Coronary Angiography With or Without Intervention.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06429345

Enrollment

250

Registered

2024-05-28

Start date

2024-06-15

Completion date

2024-11-01

Last updated

2024-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-induced Nephropathy

Brief summary

In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

Detailed description

Patients who fulfilled the inclusion criteria and agreed to participate in the study will be randomly divided into 2 groups using their computer generated random numbers that group a will receive the coenzyme Q10 in addition to the standard preventive measures and group b will receive only the standard preventive measures without the coenzyme Q10.

Interventions

DRUGCoenzyme Q10 100 Milligrams Oral Capsule

Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.

DRUGPlacebo

placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are 18 years or older. * ST-elevation myocardial infarction (STEMI). * Non ST-elevation myocardial infarction( NSTEMI). * Unstable Angina (UA)

Exclusion criteria

* Renal transplant patients. * Preoperative bleeding . * Intraoperative bleeding or hypotension. * Patients taking any nephrotoxic medications

Design outcomes

Primary

Measure	Time frame	Description
Percentage of the Creatinine rise in 1st 48-72 hours in ccu	48-72 hours	a rise in serum creatinine of at least 0.5 mg/dL or a 25% increase from baseline within 48 to 72 hours after contrast exposure

Countries

Egypt

Contacts

Primary ContactRamy Mohamed, Resident

96ramymohamed22@gmail.com01002820102

Backup ContactRamy Mohamed mostafa, Resident